Clinical Trial Update: A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating switching to Picankibart in Chinese patients with plaque psoriasis who had an inadequate response to IL-17 monoclonal antibo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Picankibart

Snippet

Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING